Incidental finding of transthyretin myocardial amyloidosis in a patient with neurological symptoms and unexplained skeletal pain on bone scintigraphy using 99mTc-DPD: A case report.

IF 0.9 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Milos Stevic, Filip Velickovic, Tamara Andjelkovic, Nina Topic
{"title":"Incidental finding of transthyretin myocardial amyloidosis in a patient with neurological symptoms and unexplained skeletal pain on bone scintigraphy using <sup>99m</sup>Tc-DPD: A case report.","authors":"Milos Stevic, Filip Velickovic, Tamara Andjelkovic, Nina Topic","doi":"10.1967/s002449912788","DOIUrl":null,"url":null,"abstract":"<p><p>Hereditary transthyretin amyloidosis (hATTR) is considered a rare disease. This is precisely why there are cases of undiagnosed transthyretin amyloidosis, in patients present with restrictive cardiomyopathy, with or without neurological or other symptoms. There are cases of incidental detection of hATTR in patients with cardiac or neurological symptoms using whole-body scintigraphy with diphosphonates. In this paper, we present the accidental detection of hATTR in a 65-year-old patient with neurological and cardiac symptoms, who was referred for skeletal scintigraphy with skeletally avid radiopharmaceuticals due to skeletal pain of unknown origin. Significantly increased uptake of radiopharmaceuticals in the myocardium was observed, corresponding to a Perugini score of 3, with semi-quantification of the heart/contralateral lung fixation ratio (H/CL) of 2.6 in the second hour after radiopharmaceutical application. Ultrasound of the heart was in favor of concentric cardiomyopathy. Due to the high suspicion of hATTR, a genetic test was performed, which showed a pathological mutation of the gene for transthyretin. Hereditary hTTR is probably a more common disease than reported in the literature. Using hATTR detection algorithms and raising awareness of the possible existence of this disease, timely diagnosis using scintigraphy with bone avid radiopharmaceuticals and appropriate therapy can help patients and their close relatives.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hellenic journal of nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1967/s002449912788","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Hereditary transthyretin amyloidosis (hATTR) is considered a rare disease. This is precisely why there are cases of undiagnosed transthyretin amyloidosis, in patients present with restrictive cardiomyopathy, with or without neurological or other symptoms. There are cases of incidental detection of hATTR in patients with cardiac or neurological symptoms using whole-body scintigraphy with diphosphonates. In this paper, we present the accidental detection of hATTR in a 65-year-old patient with neurological and cardiac symptoms, who was referred for skeletal scintigraphy with skeletally avid radiopharmaceuticals due to skeletal pain of unknown origin. Significantly increased uptake of radiopharmaceuticals in the myocardium was observed, corresponding to a Perugini score of 3, with semi-quantification of the heart/contralateral lung fixation ratio (H/CL) of 2.6 in the second hour after radiopharmaceutical application. Ultrasound of the heart was in favor of concentric cardiomyopathy. Due to the high suspicion of hATTR, a genetic test was performed, which showed a pathological mutation of the gene for transthyretin. Hereditary hTTR is probably a more common disease than reported in the literature. Using hATTR detection algorithms and raising awareness of the possible existence of this disease, timely diagnosis using scintigraphy with bone avid radiopharmaceuticals and appropriate therapy can help patients and their close relatives.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
6.70%
发文量
34
审稿时长
>12 weeks
期刊介绍: The Hellenic Journal of Nuclear Medicine published by the Hellenic Society of Nuclear Medicine in Thessaloniki, aims to contribute to research, to education and cover the scientific and professional interests of physicians, in the field of nuclear medicine and in medicine in general. The journal may publish papers of nuclear medicine and also papers that refer to related subjects as dosimetry, computer science, targeting of gene expression, radioimmunoassay, radiation protection, biology, cell trafficking, related historical brief reviews and other related subjects. Original papers are preferred. The journal may after special agreement publish supplements covering important subjects, dully reviewed and subscripted separately.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信